Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years.

Next Previous
Trial Profile

An Efficacy and Safety Study of Reslizumab (CTx55700) in the Treatment of Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years.

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 16 Sep 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Reslizumab (Primary)
  • Indications Eosinophilic oesophagitis
  • Focus Therapeutic Use
  • Sponsors Ception Therapeutics

Most Recent Events

  • 10 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 10 May 2011 Results presented at the Digestive Disease Week 2011.
  • 30 Sep 2009 Actual patient number (226) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top